Dr. Reisner is chair of the scientific advisory board for Cell Source and has equity in the company. These financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.

Called cryoablation, the procedure has not been federally approved for breast cancer treatment, but clinical trials are ...

Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer -- Follows recent Orphan Drug designation in ...